Inside CAR-T Therapy For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D.
We love to hear from our listeners. Send us a message.
Amit Kumar, Ph.D., President and CEO at Anixa Biosciences details the company’s progress on its Phase 1 trial for ovarian cancer. We also discuss why the company’s ovarian cancer program is integral for initial proof of concept for other solid tumor indications. He covers why CAR-T therapy uses an existing hormone/hormone receptor relationship to create a targeted approach to treat ovarian cancer. Dr. Kumar shares how the field of cell therapy may evolve in the short term, and much more.
Create your
podcast in
minutes
It is Free